Animal models for opioid addiction drug discovery

Shaness A. Grenald, Tally M. Largent-Milnes, Todd W Vanderah

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Since ancient times, the opium poppy has been used in a variety of settings, including pain management. Natural and synthetic derivatives of opium are commonly used in medicine today and include drugs, such as morphine, codeine, hydromorphone and oxycodone. Although excellent at inhibiting pain, these narcotics often produce a state of euphoria leading to misuse and abuse by the general population, particularly in young adults. The misuse of prescription opiates has continually increased over the past 10 years despite associated negative outcomes, resulting in opiate psychological dependence, withdrawal and relapse.Areas covered: This paper briefly refers to the history of opiate use and the modern challenges associated with chronic exposure. The authors present the prevalence of addiction and misuse of prescription opiates and discuss some of the opiate-Associated effects. This includes activation of reward circuitry and compensatory receptor mechanisms. Finally, the authors provide a review on neuroadaptive changes that manifest during opiate dependence, withdrawal and relapse in animal models.Expert opinion: In spite of the various methods available to treat opiate addiction, there is still a huge unmet need for its management, including the creative design of novel, non-Addictive pain medications. The authors believe that multifunctional compounds or combinations of compounds that inhibit pain pathways, whereas not activating the reward pathways, will begin to subdue the opiate addiction endemic.

Original languageEnglish (US)
Pages (from-to)1345-1354
Number of pages10
JournalExpert Opinion on Drug Discovery
Volume9
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Opiate Alkaloids
Opioid-Related Disorders
Drug Discovery
Opioid Analgesics
Animal Models
Reward
Pain
Prescriptions
Hydromorphone
Papaver
Oxycodone
Opium
Recurrence
Codeine
Narcotics
Expert Testimony
Pain Management
Morphine
Young Adult
History

Keywords

  • Addiction
  • Animal models
  • Neuroadaptations
  • Opioids

ASJC Scopus subject areas

  • Drug Discovery
  • Medicine(all)

Cite this

Animal models for opioid addiction drug discovery. / Grenald, Shaness A.; Largent-Milnes, Tally M.; Vanderah, Todd W.

In: Expert Opinion on Drug Discovery, Vol. 9, No. 11, 01.11.2014, p. 1345-1354.

Research output: Contribution to journalArticle

Grenald, Shaness A. ; Largent-Milnes, Tally M. ; Vanderah, Todd W. / Animal models for opioid addiction drug discovery. In: Expert Opinion on Drug Discovery. 2014 ; Vol. 9, No. 11. pp. 1345-1354.
@article{59bf185f4cbe4e24af82cfc196a6f638,
title = "Animal models for opioid addiction drug discovery",
abstract = "Introduction: Since ancient times, the opium poppy has been used in a variety of settings, including pain management. Natural and synthetic derivatives of opium are commonly used in medicine today and include drugs, such as morphine, codeine, hydromorphone and oxycodone. Although excellent at inhibiting pain, these narcotics often produce a state of euphoria leading to misuse and abuse by the general population, particularly in young adults. The misuse of prescription opiates has continually increased over the past 10 years despite associated negative outcomes, resulting in opiate psychological dependence, withdrawal and relapse.Areas covered: This paper briefly refers to the history of opiate use and the modern challenges associated with chronic exposure. The authors present the prevalence of addiction and misuse of prescription opiates and discuss some of the opiate-Associated effects. This includes activation of reward circuitry and compensatory receptor mechanisms. Finally, the authors provide a review on neuroadaptive changes that manifest during opiate dependence, withdrawal and relapse in animal models.Expert opinion: In spite of the various methods available to treat opiate addiction, there is still a huge unmet need for its management, including the creative design of novel, non-Addictive pain medications. The authors believe that multifunctional compounds or combinations of compounds that inhibit pain pathways, whereas not activating the reward pathways, will begin to subdue the opiate addiction endemic.",
keywords = "Addiction, Animal models, Neuroadaptations, Opioids",
author = "Grenald, {Shaness A.} and Largent-Milnes, {Tally M.} and Vanderah, {Todd W}",
year = "2014",
month = "11",
day = "1",
doi = "10.1517/17460441.2014.966076",
language = "English (US)",
volume = "9",
pages = "1345--1354",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Animal models for opioid addiction drug discovery

AU - Grenald, Shaness A.

AU - Largent-Milnes, Tally M.

AU - Vanderah, Todd W

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Introduction: Since ancient times, the opium poppy has been used in a variety of settings, including pain management. Natural and synthetic derivatives of opium are commonly used in medicine today and include drugs, such as morphine, codeine, hydromorphone and oxycodone. Although excellent at inhibiting pain, these narcotics often produce a state of euphoria leading to misuse and abuse by the general population, particularly in young adults. The misuse of prescription opiates has continually increased over the past 10 years despite associated negative outcomes, resulting in opiate psychological dependence, withdrawal and relapse.Areas covered: This paper briefly refers to the history of opiate use and the modern challenges associated with chronic exposure. The authors present the prevalence of addiction and misuse of prescription opiates and discuss some of the opiate-Associated effects. This includes activation of reward circuitry and compensatory receptor mechanisms. Finally, the authors provide a review on neuroadaptive changes that manifest during opiate dependence, withdrawal and relapse in animal models.Expert opinion: In spite of the various methods available to treat opiate addiction, there is still a huge unmet need for its management, including the creative design of novel, non-Addictive pain medications. The authors believe that multifunctional compounds or combinations of compounds that inhibit pain pathways, whereas not activating the reward pathways, will begin to subdue the opiate addiction endemic.

AB - Introduction: Since ancient times, the opium poppy has been used in a variety of settings, including pain management. Natural and synthetic derivatives of opium are commonly used in medicine today and include drugs, such as morphine, codeine, hydromorphone and oxycodone. Although excellent at inhibiting pain, these narcotics often produce a state of euphoria leading to misuse and abuse by the general population, particularly in young adults. The misuse of prescription opiates has continually increased over the past 10 years despite associated negative outcomes, resulting in opiate psychological dependence, withdrawal and relapse.Areas covered: This paper briefly refers to the history of opiate use and the modern challenges associated with chronic exposure. The authors present the prevalence of addiction and misuse of prescription opiates and discuss some of the opiate-Associated effects. This includes activation of reward circuitry and compensatory receptor mechanisms. Finally, the authors provide a review on neuroadaptive changes that manifest during opiate dependence, withdrawal and relapse in animal models.Expert opinion: In spite of the various methods available to treat opiate addiction, there is still a huge unmet need for its management, including the creative design of novel, non-Addictive pain medications. The authors believe that multifunctional compounds or combinations of compounds that inhibit pain pathways, whereas not activating the reward pathways, will begin to subdue the opiate addiction endemic.

KW - Addiction

KW - Animal models

KW - Neuroadaptations

KW - Opioids

UR - http://www.scopus.com/inward/record.url?scp=84911463862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911463862&partnerID=8YFLogxK

U2 - 10.1517/17460441.2014.966076

DO - 10.1517/17460441.2014.966076

M3 - Article

C2 - 25307021

AN - SCOPUS:84911463862

VL - 9

SP - 1345

EP - 1354

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 11

ER -